PlainPharmaWatch

CMS Open Payments · Program Year 2024

Avirmax Biopharma, Inc

Avirmax Biopharma, Inc reported $631.49 across General Payments, Research, and Ownership to 5 physicians and teaching hospitals across 5 transactions.

See the rankings → How this is sourced
$631.49 Below-median payer
All-tracks total
5 Below-median volume
Transactions
5 Below-median reach
Recipients
#1866
of 1,925 companies

Avirmax Biopharma, Inc reported $631.49 across all CMS Open Payments tracks (General + Research + Ownership) to 5 physicians and teaching hospitals in Program Year 2024 - ranking #1866 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $631.49, averaging $126.30 per recipient.

Avirmax Biopharma, Inc's payment reach score

Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.

Overall reach score

F

13/100

Total payments

F

10/100

Transaction volume

F

10/100

Physician reach

F

10/100

Payment type diversity

F

23/100

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer avirmax-biopharma-inc Avirmax Biopharma, Inc

$631.49 · #1866/1,925 · 0.0% industry · PY2024

  • TOT $631.49
  • RANK #1866
  • SHARE 0.0%
  • TXN 5
  • RCP 5
  • CAT 2
  • GEN $631.49
  • TOP1 28.7%
  • PY 2024

Volume peers

Nearest volume peer: aap Implants Inc ($631.69)

aap Implants Inc$631.69Avirmax Biopharma, Inc (this)$631.49Mf Med$630.54Nurami Medical Ltd$627.48curasan, Inc.$621.57
All-tracks payment totals near Avirmax Biopharma, Inc (CMS Open Payments PY2024)

Avirmax Biopharma, Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

What the Data Shows for Avirmax Biopharma, Inc

Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Avirmax Biopharma, Inc that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.

"Gift" leads the 2-category general-payment breakdown below at $600.00 (95.0% of General Payments, 4 transactions) - see our methodology for how research and ownership payments are reported separately.

General Payment Breakdown by Type

Avirmax Biopharma, Inc made 2 types of general payments. "Gift" is the largest category at $600.00, 95.0% of General Payments.

How Avirmax Biopharma, Inc divides its payments

Ranked by total dollars reported per category

1. Gift$600.002. Food and Beverage$31.49
Payment Type Amount Transactions
Gift $600.00 4
Food and Beverage $31.49 1

Recipient Concentration in General Payments

The five largest recipient relationships account for $631.49 (100.0%) of $631.49 in this company's General Payments records across 4 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Avirmax Biopharma, Inc

The five named recipients with the highest reported General Payments from this company

Roger Goldberg$181.49Richard Lane$150.00Charles Wykoff$150.00Dilsher Dhoot$150.00
  1. 1

    Roger Goldberg

    $181.49 across 2 reported transactions

  2. 2

    Richard Lane

    $150.00 across 1 reported transactions

  3. 3

    Charles Wykoff

    $150.00 across 1 reported transactions

  4. 4

    Dilsher Dhoot

    $150.00 across 1 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Spend vs. Concentration

Avirmax Biopharma, Inc ranks #1866 of 1,925 by total payments (bottom 3% by spend) but is notably more concentrated than that alone would suggest -- #643 of 1,838 by HHI (top 35% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.

01.83.75.57.32494.92511.925292546.12563.1Total payments ($M)Concentration (HHI, 0-10,000)
Avirmax Biopharma, Inc (highlighted) among its 12 nearest HHI-concentration neighbors, Program Year 2024. Dashed lines mark this neighborhood's median payment total and median HHI. Hover a point for the company name. Source: company_concentration (CMS Open Payments general-payment recipients).
View all 12 companies in this HHI neighborhood as a list

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Avirmax Biopharma, Inc's, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Avirmax Biopharma, Inc.

Oxford Performance Materials, Inc.

HHI 2520

IBSA Institut Biochimique SA

HHI 2512

Boehringer Ingelheim RCV GmbH & Co KG

HHI 2525

Aidoc Medical Ltd

HHI 2529

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Avirmax Biopharma, Inc.

Showing 6 of 1,924 companies with CMS-reported payment data.

Put this to use

Avirmax Biopharma, Inc ranks #1866 of 1,925 by all-tracks total payments, led by "Gift".

Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Avirmax Biopharma, Inc's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.